FDA approves new Exalenz H. Pylori bacteria test

The BID Hp system is an upgraded version of Exalenz's BreathID device for the detection of the H. Pylori bacteria, a cause of gastric ulcers.

Exalenz Bioscience Ltd. (TASE:EXEN) has obtained US Food and Drug Administration (FDA) approval for marketing its new BreathID system for the detection of the H. Pylori bacteria, a cause of gastric ulcers. Exalenz spent years developing the system, including clinical trials on 330 patients in the US and Israel. The FDA approval came several weeks after EU CE Mark certification of the system.

The BID Hp system is an upgraded version of Exalenz's BreathID device, which is already sold in the US.

Exalenz CEO Lawrence Cohen said, "After years of development and successful completion of clinical trials on hundreds of patients in the US and Israel, Exalenz is launching its new system with unparalleled performance. Through the sales and market network we have established in the past few months, we expect strong improvement in the company's performance from the third quarter."

Exalenz's share price rose 26% by early afternoon to NIS 0.155, giving a market cap of NIS 75 million.

Published by Globes [online], Israel business news - www.globes-online.com - on May 26, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018